Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Completed · Phase 1
Conditions studied: Non-small Cell Lung Cancer
In brief
The purpose of this research study is to determine the maximum tolerated dose of GT103 and investigate the safety and effectiveness of the study drug.
Key facts
- Study ID
- NCT04314089
- Run by
- Edward Patz
- People needed
- 31
- Starts
- 2020-06-09
- Expected to finish
- 2024-12-30
- Last updated by the study team
- 2025-06-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Advent Health — Celebration, Florida, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Duke University Medical Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.